Celcuity’s (CELC) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Celcuity (NASDAQ:CELC) in a research report sent to investors on Tuesday morning, MarketBeat.com reports. The firm currently has a $122.00 price target on the stock.

A number of other equities analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Jefferies Financial Group boosted their target price on Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Wells Fargo & Company assumed coverage on Celcuity in a research report on Friday, December 12th. They issued an “overweight” rating and a $126.00 target price on the stock. Wolfe Research reaffirmed an “outperform” rating and set a $110.00 price target on shares of Celcuity in a research note on Thursday, March 12th. Finally, HC Wainwright reiterated a “neutral” rating and set a $94.00 price target (up from $77.00) on shares of Celcuity in a report on Monday, November 17th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $108.63.

Celcuity Trading Up 0.4%

Shares of NASDAQ CELC opened at $112.99 on Tuesday. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. Celcuity has a one year low of $7.57 and a one year high of $120.32. The business has a 50-day moving average price of $109.43 and a two-hundred day moving average price of $88.56. The firm has a market capitalization of $5.23 billion, a PE ratio of -30.79 and a beta of 0.38.

Insiders Place Their Bets

In other Celcuity news, Director David Dalvey sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares of the company’s stock, valued at $10,802,700. This represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.77% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CELC. EverSource Wealth Advisors LLC increased its position in Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Celcuity in the fourth quarter valued at approximately $42,000. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Celcuity in the third quarter valued at approximately $27,000. US Bancorp DE grew its stake in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the last quarter. Finally, NBC Securities Inc. acquired a new stake in shares of Celcuity in the fourth quarter worth $99,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.